Literature DB >> 25249493

Epidemiology of meningiomas.

I Baldi1, J Engelhardt2, C Bonnet2, L Bauchet3, E Berteaud1, A Grüber1, H Loiseau4.   

Abstract

Although they represent about a third of all the tumors of the central nervous system, knowledge concerning meningioma epidemiology (including incidence data and exploration of the risk factors) remains scarce compared to that of gliomas. A limited number of cancer registries worldwide only record malignant brain tumors, however their completeness and accuracy have been questioned. Even if comparisons are made difficult due to differences in methodologies, available annual incidence rates (sex- and age-standardized, generally on US or World standard population), provided by population-based registries range from 1.3/100,000 to 7.8/100,000 for cerebral meningiomas. An increase in the incidence of primary brain tumors in general and of meningiomas in particular has been observed during the past decades in several countries. It has been suggested that this trend could be artefactual and could be the resultant of an ageing population, improvement in health access and in diagnostic procedures, changes in coding classification for tumors recorded in registries, and/or an increase in the rate of histological confirmation, even in the elderly. All these factors are likely to play a role but they might not fully explain the increase in incidence, observed in most age groups. In addition to intrinsic risk factors (gender, ethnic groups, allergic conditions, familial and personal history, genetic polymorphisms), some exogenous risk factors have been suspected to play a role in the etiology of meningiomas and their changes with time is likely to impact incidence trends. A causal link has been established only for ionising radiation but the role of many other factors have been hypothesised: electromagnetic fields, nutrition, pesticides, hormonal as well as reproductive factors. Considering the serious or even lethal potentiality of some meningiomas and the apparent rise in their incidence, all practitioners involved in neuro-oncology should feel concerned today of the necessity to better assess their public health burden and to study their epidemiological features.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Brain tumors; Epidemiology; Facteurs de risque; Incidence; Meningioma; Méningiomes; Registre; Registry; Risk factor; Tumeur cérébrale; Épidémiologie

Mesh:

Year:  2014        PMID: 25249493     DOI: 10.1016/j.neuchi.2014.05.006

Source DB:  PubMed          Journal:  Neurochirurgie        ISSN: 0028-3770            Impact factor:   1.553


  26 in total

1.  Improving Forward Infusion Pressure during Brain Tumor Embolization with the Double Catheter and Coil Technique.

Authors:  Sam Dayawansa; Sneha Konda; Walter S Lesley; Patrick T Noonan; Jason H Huang
Journal:  Neurointervention       Date:  2017-09-05

2.  Clinical features, surgical management, and prognostic factors of secretory meningiomas: a single-center case series of 149 patients.

Authors:  Xiaogang Tao; Kun Wang; Jinqian Dong; Zonggang Hou; Zhen Wu; Junting Zhang; Baiyun Liu
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

3.  WHO grade of intracranial meningiomas differs with respect to patient's age, location, tumor size and peritumoral edema.

Authors:  Anne Ressel; Susanne Fichte; Michael Brodhun; Steffen K Rosahl; Ruediger Gerlach
Journal:  J Neurooncol       Date:  2019-10-01       Impact factor: 4.130

4.  Management of symptomatic hemifacial spasm or trigeminal neuralgia.

Authors:  Ming-Xing Liu; Jun Zhong; Ning-Ning Dou; Lei Xia; Bin Li; Shi-Ting Li
Journal:  Neurosurg Rev       Date:  2016-02-15       Impact factor: 3.042

5.  Cyproterone acetate and meningioma: a nationwide-wide population based study.

Authors:  Charles Champeaux-Depond; Joconde Weller; Sebastien Froelich; Agnes Sartor
Journal:  J Neurooncol       Date:  2021-01-04       Impact factor: 4.130

6.  Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma.

Authors:  Edouard Samarut; Alexandre Lugat; Aymeric Amelot; Emeric Scharbarg; Samy Hadjadj; Claire Primot; Delphine Loussouarn; François Thillays; Kevin Buffenoir; Bertrand Cariou; Delphine Drui; Vincent Roualdes
Journal:  J Neurooncol       Date:  2021-01-03       Impact factor: 4.130

7.  Mitochondrial DNA sequence variation and risk of meningioma.

Authors:  Claudine M Samanic; Jamie K Teer; Zachary J Thompson; Jordan H Creed; Sepideh Mokhtari; Brooke L Fridley; L Burt Nabors; Sion L Williams; Kathleen M Egan
Journal:  J Neurooncol       Date:  2021-10-20       Impact factor: 4.130

8.  Gamma Knife Stereotactic Radiosurgery for Grade 2 Meningiomas.

Authors:  Tamer Refaat; Michelle Gentile; Sean Sachdev; Prarthana Dalal; Anish Butala; Stanley Gutiontov; Irene Helenowksi; Plato Lee; Vythialinga Sathiaseelan; Orin Bloch; James Chandler; John A Kalapurakal
Journal:  J Neurol Surg B Skull Base       Date:  2017-02-01

Review 9.  Meningioma Tumor Microenvironment.

Authors:  Sajad Sahab-Negah; Ali Gorji
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

10.  Meningioma Surgery in Patients ≥70 Years of Age: Clinical Outcome and Validation of the SKALE Score.

Authors:  Daniel Monden; Florian J Raimann; Vanessa Neef; Daniel Dubinski; Florian Gessler; Fee Keil; Marie-Thérèse Forster; Michael W Ronellenfitsch; Patrick N Harter; Thomas M Freiman; Elke Hattingen; Volker Seifert; Christian Senft; Peter Baumgarten
Journal:  J Clin Med       Date:  2021-04-22       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.